Results 11 to 20 of about 34,385 (232)

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. [PDF]

Blood Cancer J, 2023
Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D'Souza A.   +5 more
europepmc   +4 more sources

The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis. [PDF]

Amyloid, 2020
Background: The diagnostic utility of repeat kidney biopsy in AL amyloidosis patients in complete (CR) or very good partial hematologic response (VGPR) but with renal organ relapse is not clear.
Angel-Korman A, Jaberi A, Sanchorawala V, Havasi A.   +3 more
europepmc   +4 more sources

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient

Nature Communications, 2019
Immunoglobulin Light Chain Amyloidosis (AL) is the most common systemic amyloidosis occurring in Western countries. Here the authors present the 4.0 Å cryo-EM structure of light chain AL55 fibrils that were isolated from the heart of an AL systemic ...
Paolo Swuec, Francesca Lavatelli, Masayoshi Tasaki, Cristina Paissoni, Paola Rognoni, Martina Maritan, Francesca Brambilla, Paolo Milani, Pierluigi Mauri, Carlo Camilloni, Giovanni Palladini, Giampaolo Merlini, Stefano Ricagno, Martino Bolognesi   +13 more
doaj   +4 more sources

Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. [PDF]

Haematologica, 2018
A 67-year-old male presented with a one-year history of fatigue, cold intolerance, malaise and an unintentional weight loss of ~80 lbs over the course of the preceding 12 months.
Leung N, Thomé SD, Dispenzieri A.
europepmc   +4 more sources

Suggestive Diagnostic Process in a Case of Multiple Myeloma with Gastrointestinal Immunoglobulin Light-Chain Amyloidosis Accompanied by Protein-Losing Enteropathy [PDF]

Case Reports in Gastrointestinal Medicine, 2021
Multiple myeloma is a type of plasma cell neoplasm that produces monoclonal immunoglobulin. Multiple myeloma is known to cause immunoglobulin light-chain (AL) amyloidosis, which frequently involves the kidney and heart.
Katsuya Endo, Takehito Ito, Jun Nomura, Keigo Murakami, Shiho Kondo, Tomonori Satoh, Daisuke Fukushi, Yuki Yoshino, Yoshiteru Sasaki, Atsuko Takasu, Takayuki Kogure, Morihisa Hirota, Takayoshi Meguro, Kazuhiro Murakami, Junichi Kameoka, Kennichi Satoh   +15 more
doaj   +4 more sources

Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment [PDF]

American journal of hematology/oncology, 2018
Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues.
M. Gertz
semanticscholar   +2 more sources

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. [PDF]

New England Journal of Medicine, 2021
BACKGROUND Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease.
E. Kastritis, G. Palladini, M. Minnema, A. Wechalekar, A. Jaccard, Hans C. Lee, V. Sanchorawala, S. Gibbs, P. Mollee, C. Venner, Jin-Hai Lu, S. Schönland, M. Gatt, Kenshi Suzuki, Kihyun Kim, M. Cibeira, M. Beksaç, E. Libby, J. Valent, V. Hungria, S. Wong, M. Rosenzweig, N. Bumma, A. Huart, M. Dimopoulos, D. Bhutani, A. Waxman, S. Goodman, J. Zonder, Selay Lam, K. Song, T. Hansen, S. Manier, W. Roeloffzen, K. Jamroziak, F. Kwok, C. Shimazaki, Jin-Seok Kim, E. Crusoé, T. Ahmadi, N. Tran, X. Qin, S. Vasey, B. Tromp, J. Schecter, B. Weiss, S. Zhuang, J. Vermeulen, G. Merlini, R. Comenzo   +49 more
semanticscholar   +2 more sources

An updated AL-Base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis

bioRxiv
Background Each monoclonal antibody light chain associated with AL amyloidosis has a unique sequence. Defining how these sequences lead to amyloid deposition could facilitate faster diagnosis and lead to new treatments.
Gareth J Morgan, Allison N. Nau, Sherry Wong, Brian H Spencer, Yun Shen, Axin Hua, Matthew J. Bullard, V. Sanchorawala, Tatiana Prokaeva   +8 more
semanticscholar   +2 more sources

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. [PDF]

Blood Cancer J, 2020
Rarity of light-chain amyloidosis (AL) makes randomized studies challenging. We pooled three phase II studies of immunomodulatory drugs (IMiDs) to update survival, toxicity, and assess new response/progression criteria. Studies included were lenalidomide-
Warsame R, LaPlant B, Kumar SK, Laumann K, Perez Burbano G, Buadi FK, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Lust J, Russell SJ, Zeldenrust S, Lin Y, Muchtar E, Go RS, Vincent Rajkumar S, Dispenzieri A.   +25 more
europepmc   +2 more sources

Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up [PDF]

British Journal of Haematology, 2021
Lenalidomide and dexamethasone (RD) is a standard treatment in relapsed/refractory immunoglobulin light chain (AL) amyloidosis (RRAL). We retrospectively investigated toxicity, efficacy and prognostic markers in 260 patients with RRAL.
M. Basset, C. Kimmich, Nicholas Schreck, J. Krzykalla, T. Dittrich, K. Veelken, H. Goldschmidt, A. Seckinger, D. Hose, A. Jauch, C. Müller-Tidow, A. Benner, U. Hegenbart, S. Schönland   +13 more
semanticscholar   +2 more sources